Literature DB >> 21702050

The calcineurin-nuclear factor of activated T cells signaling pathway mediates the effect of corticotropin releasing factor and urocortins on catecholamine synthesis.

Eirini Dermitzaki1, Christos Tsatsanis, Achille Gravanis, Andrew N Margioris.   

Abstract

The biological effects of the Corticotropin-releasing factor (CRF) family of neuropeptides are mediated by mobilization of [Ca(2+)]. Aim of the current work was to examine if the calcineurin/NFAT (nuclear factor of activated T-cells) signaling pathway is involved in the effect of CRF peptides in catecholamine synthesis and secretion from PC12 rat pheochromocytona cells, a model for the study of adrenal catecholamine production. PC12 cells express both types of CRF receptors. Our data are as follows: (a) The calcineurin inhibitor cyclosporine A (CsA) blocked norepinephrine secretion induced by ligands of either CRF type 1 (CRF(1)) or 2 (CRF(2)) receptors on PC12 cells. (b) Silencing NFAT2 expression using a selective NFAT2 siRNA blocked CRF(1) and CRF(2) -induced NE production. (c) CRF ligands induced NFAT transcriptional activity in cells transfected with a luciferase reporter construct controlled by NFAT binding elements (NFAT-Luc). (d) CsA completely blocked the stimulatory effect of CRF(1) and CRF(2) ligands on NFAT activity in NFAT-Luc transfected cells. (e) PKA, PKC, p38-MAPK, Tpl2, Ha-Ras, and AKT1 were crucial intermediates for both CRF(1) and CRF(2)-induced NFAT activation. Interestingly, MEK1/2 and ERK1/2 were crucial only for the CRF(2)-induced NFAT activation. (f) p38-MAPK and Tpl2 were crucial intermediates for both CRF(1) and CRF(2)-induced norepinephrine production, while AKT1 affected only CRF(2)-induced norepinephrine production. In conclusion, our data suggest that CRF(1) and CRF(2) ligands activate the transcription factor NFAT and its activation is prerequisite for CRF-induced catecholamine production from chromaffin cells.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21702050     DOI: 10.1002/jcp.22914

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  6 in total

1.  MicroRNA 375 mediates the signaling pathway of corticotropin-releasing factor (CRF) regulating pro-opiomelanocortin (POMC) expression by targeting mitogen-activated protein kinase 8.

Authors:  Nan Zhang; Jun-kai Lin; Juan Chen; Xiong-fei Liu; Jia-li Liu; Hao-shu Luo; Yue-qin Li; Sheng Cui
Journal:  J Biol Chem       Date:  2013-02-21       Impact factor: 5.157

2.  NFAT transcription factor regulation by urocortin II in cardiac myocytes and heart failure.

Authors:  Stefanie Walther; Sawsan Awad; Vassyl A Lonchyna; Lothar A Blatter
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-01-17       Impact factor: 4.733

Review 3.  Calcineurin signaling as a target for the treatment of alcohol abuse and neuroinflammatory disorders.

Authors:  Patrick J Ronan; Sarah A Flynn; Thomas P Beresford
Journal:  Prog Mol Biol Transl Sci       Date:  2019-08-12       Impact factor: 3.622

4.  Central Administration of Cyclosporine A Decreases Ethanol Drinking.

Authors:  Patrick J Ronan; Sydney A Strait; Geralyn M Palmer; Thomas P Beresford
Journal:  Alcohol Alcohol       Date:  2018-03-01       Impact factor: 2.826

5.  Activation of CRH receptor type 1 expressed on glutamatergic neurons increases excitability of CA1 pyramidal neurons by the modulation of voltage-gated ion channels.

Authors:  Stephan Kratzer; Corinna Mattusch; Michael W Metzger; Nina Dedic; Michael Noll-Hussong; Karl W Kafitz; Matthias Eder; Jan M Deussing; Florian Holsboer; Eberhard Kochs; Gerhard Rammes
Journal:  Front Cell Neurosci       Date:  2013-07-19       Impact factor: 5.505

6.  Calcineurin/NFAT signaling represses genes Vamp1 and Vamp2 via PMCA-dependent mechanism during dopamine secretion by Pheochromocytoma cells.

Authors:  Michalina Kosiorek; Ludmila Zylinska; Krzysztof Zablocki; Slawomir Pikula
Journal:  PLoS One       Date:  2014-03-25       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.